Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Karlén A[au]:

SOX5/6/21 Prevent Oncogene-Driven Transformation of Brain Stem Cells. Kurtsdotter I et al. Cancer Res. (2017)

Discovery and preclinical development of new antibiotics. Hughes D et al. Ups J Med Sci. (2014)

Predicting the Rate of Skin Penetration Using an Aggregated Conformal Prediction Framework. Lindh M et al. Mol Pharm. (2017)

Search results

Items: 1 to 50 of 121

1.

Boronic ester-linked macrocyclic lipopeptides as serine protease inhibitors targeting Escherichia coli type I signal peptidase.

Szałaj N, Lu L, Benediktsdottir A, Zamaratski E, Cao S, Olanders G, Hedgecock C, Karlén A, Erdélyi M, Hughes D, Mowbray SL, Brandt P.

Eur J Med Chem. 2018 Sep 5;157:1346-1360. doi: 10.1016/j.ejmech.2018.08.086. Epub 2018 Aug 30.

PMID:
30196059
2.

Orthopaedic Surgery Residency Rotations and Correlation With Orthopaedic In-Training Examination Performance.

Karlen AI, Solberg EJ, Quanbeck DS, Van Heest AE.

J Surg Educ. 2018 Sep - Oct;75(5):1325-1328. doi: 10.1016/j.jsurg.2018.01.018. Epub 2018 Feb 12.

PMID:
29449163
3.

SOX5/6/21 Prevent Oncogene-Driven Transformation of Brain Stem Cells.

Kurtsdotter I, Topcic D, Karlén A, Singla B, Hagey DW, Bergsland M, Siesjö P, Nistér M, Carlson JW, Lefebvre V, Persson O, Holmberg J, Muhr J.

Cancer Res. 2017 Sep 15;77(18):4985-4997. doi: 10.1158/0008-5472.CAN-17-0704. Epub 2017 Jul 7.

4.

Predicting the Rate of Skin Penetration Using an Aggregated Conformal Prediction Framework.

Lindh M, Karlén A, Norinder U.

Mol Pharm. 2017 May 1;14(5):1571-1576. doi: 10.1021/acs.molpharmaceut.7b00007. Epub 2017 Apr 17.

PMID:
28335598
5.

Docking of Macrocycles: Comparing Rigid and Flexible Docking in Glide.

Alogheli H, Olanders G, Schaal W, Brandt P, Karlén A.

J Chem Inf Model. 2017 Feb 27;57(2):190-202. doi: 10.1021/acs.jcim.6b00443. Epub 2017 Feb 2.

PMID:
28079375
6.

Design, synthesis and in vitro biological evaluation of oligopeptides targeting E. coli type I signal peptidase (LepB).

De Rosa M, Lu L, Zamaratski E, Szałaj N, Cao S, Wadensten H, Lenhammar L, Gising J, Roos AK, Huseby DL, Larsson R, Andrén PE, Hughes D, Brandt P, Mowbray SL, Karlén A.

Bioorg Med Chem. 2017 Feb 1;25(3):897-911. doi: 10.1016/j.bmc.2016.12.003. Epub 2016 Dec 7.

7.

Lentivirus Mediated Correction of Artemis-Deficient Severe Combined Immunodeficiency.

Punwani D, Kawahara M, Yu J, Sanford U, Roy S, Patel K, Carbonaro DA, Karlen AD, Khan S, Cornetta K, Rothe M, Schambach A, Kohn DB, Malech HL, McIvor RS, Puck JM, Cowan MJ.

Hum Gene Ther. 2017 Jan;28(1):112-124. doi: 10.1089/hum.2016.064. Epub 2016 Sep 7.

8.

The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance.

Kostyanev T, Bonten MJ, O'Brien S, Steel H, Ross S, François B, Tacconelli E, Winterhalter M, Stavenger RA, Karlén A, Harbarth S, Hackett J, Jafri HS, Vuong C, MacGowan A, Witschi A, Angyalosi G, Elborn JS, deWinter R, Goossens H.

J Antimicrob Chemother. 2016 Feb;71(2):290-5. doi: 10.1093/jac/dkv339. Epub 2015 Nov 15. Review.

PMID:
26568581
9.

Optimization and Evaluation of 5-Styryl-Oxathiazol-2-one Mycobacterium tuberculosis Proteasome Inhibitors as Potential Antitubercular Agents.

Russo F, Gising J, Åkerbladh L, Roos AK, Naworyta A, Mowbray SL, Sokolowski A, Henderson I, Alling T, Bailey MA, Files M, Parish T, Karlén A, Larhed M.

ChemistryOpen. 2015 Jun;4(3):342-62. doi: 10.1002/open.201500001. Epub 2015 Apr 17.

10.

Role of transgene regulation in ex vivo lentiviral correction of artemis deficiency.

Multhaup MM, Podetz-Pedersen KM, Karlen AD, Olson ER, Gunther R, Somia NV, Blazar BR, Cowan MJ, McIvor RS.

Hum Gene Ther. 2015 Apr;26(4):232-43. doi: 10.1089/hum.2014.062. Epub 2015 Apr 13.

11.

Interconversion of Functional Activity by Minor Structural Alterations in Nonpeptide AT2 Receptor Ligands.

Wallinder C, Sköld C, Botros M, Guimond MO, Hallberg M, Gallo-Payet N, Karlén A, Alterman M.

ACS Med Chem Lett. 2014 Dec 8;6(2):178-82. doi: 10.1021/ml500427r. eCollection 2015 Feb 12.

12.

Phototriggerable peptidomimetics for the inhibition of Mycobacterium tuberculosis ribonucleotide reductase by targeting protein-protein binding.

Karlsson C, Blom M, Johansson M, Jansson AM, Scifo E, Karlén A, Govender T, Gogoll A.

Org Biomol Chem. 2015 Mar 7;13(9):2612-21. doi: 10.1039/c4ob01926a.

PMID:
25580895
13.

Toward a benchmarking data set able to evaluate ligand- and structure-based virtual screening using public HTS data.

Lindh M, Svensson F, Schaal W, Zhang J, Sköld C, Brandt P, Karlén A.

J Chem Inf Model. 2015 Feb 23;55(2):343-53. doi: 10.1021/ci5005465. Epub 2015 Jan 28.

PMID:
25564966
14.

Vinylated linear P2 pyrimidinyloxyphenylglycine based inhibitors of the HCV NS3/4A protease and corresponding macrocycles.

Lampa A, Alogheli H, Ehrenberg AE, Åkerblom E, Svensson R, Artursson P, Danielson UH, Karlén A, Sandström A.

Bioorg Med Chem. 2014 Dec 1;22(23):6595-6615. doi: 10.1016/j.bmc.2014.10.010.

PMID:
25456385
15.

Novel Peptidomimetic Hepatitis C Virus NS3/4A Protease Inhibitors Spanning the P2-P1' Region.

Lampa AK, Bergman SM, Gustafsson SS, Alogheli H, Akerblom EB, Lindeberg GG, Svensson RM, Artursson P, Danielson UH, Karlén A, Sandström A.

ACS Med Chem Lett. 2013 Aug 2;5(3):249-54. doi: 10.1021/ml400217r. eCollection 2014 Mar 13.

16.

Discovery and preclinical development of new antibiotics.

Hughes D, Karlén A.

Ups J Med Sci. 2014 May;119(2):162-9. doi: 10.3109/03009734.2014.896437. Epub 2014 Mar 19. Review.

17.

DXR inhibition by potent mono- and disubstituted fosmidomycin analogues.

Jansson AM, Więckowska A, Björkelid C, Yahiaoui S, Sooriyaarachchi S, Lindh M, Bergfors T, Dharavath S, Desroses M, Suresh S, Andaloussi M, Nikhil R, Sreevalli S, Srinivasa BR, Larhed M, Jones TA, Karlén A, Mowbray SL.

J Med Chem. 2013 Aug 8;56(15):6190-9. doi: 10.1021/jm4006498. Epub 2013 Jul 17.

PMID:
23819803
18.

Achiral pyrazinone-based inhibitors of the hepatitis C virus NS3 protease and drug-resistant variants with elongated substituents directed toward the S2 pocket.

Gising J, Belfrage AK, Alogheli H, Ehrenberg A, Åkerblom E, Svensson R, Artursson P, Karlén A, Danielson UH, Larhed M, Sandström A.

J Med Chem. 2014 Mar 13;57(5):1790-801. doi: 10.1021/jm301887f. Epub 2013 Apr 2.

PMID:
23517538
19.

Novel pseudopeptides incorporating a benzodiazepine-based turn mimetic--targeting Mycobacterium tuberculosis ribonucleotide reductase.

Nurbo J, Ericsson DJ, Rosenström U, Muthas D, Jansson AM, Lindeberg G, Unge T, Karlén A.

Bioorg Med Chem. 2013 Apr 1;21(7):1992-2000. doi: 10.1016/j.bmc.2013.01.020. Epub 2013 Jan 18.

PMID:
23395111
20.

Neuronal overexpression of Nogo receptor 1 in APPswe/PSEN1(ΔE9) mice impairs spatial cognition tasks without influencing plaque formation.

Karlsson TE, Karlén A, Olson L, Josephson A.

J Alzheimers Dis. 2013;33(1):145-55. doi: 10.3233/JAD-2012-120493.

PMID:
22903127
21.

Two cases of partial hepatectomy for malignant melanoma.

Karlen AI, Clark JJ, Wong LL.

Hawaii J Med Public Health. 2012 Apr;71(4):92-6.

22.

Trisubstituted imidazoles as Mycobacterium tuberculosis glutamine synthetase inhibitors.

Gising J, Nilsson MT, Odell LR, Yahiaoui S, Lindh M, Iyer H, Sinha AM, Srinivasa BR, Larhed M, Mowbray SL, Karlén A.

J Med Chem. 2012 Mar 22;55(6):2894-8. doi: 10.1021/jm201212h. Epub 2012 Mar 8.

23.

Virtual screening data fusion using both structure- and ligand-based methods.

Svensson F, Karlén A, Sköld C.

J Chem Inf Model. 2012 Jan 23;52(1):225-32. doi: 10.1021/ci2004835. Epub 2011 Dec 22.

PMID:
22148635
24.

Synthesis of functionalized cinnamaldehyde derivatives by an oxidative Heck reaction and their use as starting materials for preparation of Mycobacterium tuberculosis 1-deoxy-D-xylulose-5-phosphate reductoisomerase inhibitors.

Nordqvist A, Björkelid C, Andaloussi M, Jansson AM, Mowbray SL, Karlén A, Larhed M.

J Org Chem. 2011 Nov 4;76(21):8986-98. doi: 10.1021/jo201715x. Epub 2011 Oct 7.

25.

Substitution of the phosphonic acid and hydroxamic acid functionalities of the DXR inhibitor FR900098: an attempt to improve the activity against Mycobacterium tuberculosis.

Andaloussi M, Lindh M, Björkelid C, Suresh S, Wieckowska A, Iyer H, Karlén A, Larhed M.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5403-7. doi: 10.1016/j.bmcl.2011.07.005. Epub 2011 Jul 20.

PMID:
21824775
26.

P2-P1' macrocyclization of P2 phenylglycine based HCV NS3 protease inhibitors using ring-closing metathesis.

Lampa A, Ehrenberg AE, Vema A, Åkerblom E, Lindeberg G, Danielson UH, Karlén A, Sandström A.

Bioorg Med Chem. 2011 Aug 15;19(16):4917-27. doi: 10.1016/j.bmc.2011.06.064. Epub 2011 Jun 28.

PMID:
21782454
27.

Design, synthesis, and X-ray crystallographic studies of α-aryl substituted fosmidomycin analogues as inhibitors of Mycobacterium tuberculosis 1-deoxy-D-xylulose 5-phosphate reductoisomerase.

Andaloussi M, Henriksson LM, Więckowska A, Lindh M, Björkelid C, Larsson AM, Suresh S, Iyer H, Srinivasa BR, Bergfors T, Unge T, Mowbray SL, Larhed M, Jones TA, Karlén A.

J Med Chem. 2011 Jul 28;54(14):4964-76. doi: 10.1021/jm2000085. Epub 2011 Jul 1.

PMID:
21678907
28.

Characterization of the human artemis promoter by heterologous gene expression in vitro and in vivo.

Multhaup MM, Gurram S, Podetz-Pedersen KM, Karlen AD, Swanson DL, Somia NV, Hackett PB, Cowan MJ, McIvor RS.

DNA Cell Biol. 2011 Oct;30(10):751-61. doi: 10.1089/dna.2011.1244. Epub 2011 Jun 10.

29.

Potent macrocyclic inhibitors of insulin-regulated aminopeptidase (IRAP) by olefin ring-closing metathesis.

Andersson H, Demaegdt H, Johnsson A, Vauquelin G, Lindeberg G, Hallberg M, Erdelyi M, Karlen A, Hallberg A.

J Med Chem. 2011 Jun 9;54(11):3779-92. doi: 10.1021/jm200036n. Epub 2011 May 9.

PMID:
21476495
30.

Disulfide cyclized tripeptide analogues of angiotensin IV as potent and selective inhibitors of insulin-regulated aminopeptidase (IRAP).

Andersson H, Demaegdt H, Vauquelin G, Lindeberg G, Karlén A, Hallberg M, Erdélyi M, Hallberg A.

J Med Chem. 2010 Nov 25;53(22):8059-71. doi: 10.1021/jm100793t. Epub 2010 Nov 3.

PMID:
21047126
31.

Olfactory ensheathing cells promote neurite outgrowth from co-cultured brain stem slice.

Jiao Y, Novozhilova E, Karlén A, Muhr J, Olivius P.

Exp Neurol. 2011 May;229(1):65-71. doi: 10.1016/j.expneurol.2010.10.008. Epub 2010 Oct 23.

PMID:
20974131
32.

Structure-activity relationships of HCV NS3 protease inhibitors evaluated on the drug-resistant variants A156T and D168V.

Ortqvist P, Vema A, Ehrenberg AE, Dahl G, Rönn R, Akerblom E, Karlén A, Danielson UH, Sandström A.

Antivir Ther. 2010;15(6):841-52. doi: 10.3851/IMP1655.

PMID:
20834096
33.

Discovery of achiral inhibitors of the hepatitis C virus NS3 protease based on 2(1H)-pyrazinones.

Ortqvist P, Gising J, Ehrenberg AE, Vema A, Borg A, Karlén A, Larhed M, Danielson UH, Sandström A.

Bioorg Med Chem. 2010 Sep 1;18(17):6512-25. doi: 10.1016/j.bmc.2010.06.101. Epub 2010 Jul 3.

PMID:
20673728
34.

Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.

Lampa A, Ehrenberg AE, Gustafsson SS, Vema A, Kerblom E, Lindeberg G, Karlén A, Danielson UH, Sandström A.

Bioorg Med Chem. 2010 Jul 15;18(14):5413-24. doi: 10.1016/j.bmc.2010.05.027. Epub 2010 May 20.

PMID:
20541424
35.

Cytotoxicity associated with artemis overexpression after lentiviral vector-mediated gene transfer.

Multhaup M, Karlen AD, Swanson DL, Wilber A, Somia NV, Cowan MJ, McIvor RS.

Hum Gene Ther. 2010 Jul;21(7):865-75. doi: 10.1089/hum.2009.162.

36.

Identification of small peptides mimicking the R2 C-terminus of Mycobacterium tuberculosis ribonucleotide reductase.

Ericsson DJ, Nurbo J, Muthas D, Hertzberg K, Lindeberg G, Karlén A, Unge T.

J Pept Sci. 2010 Mar;16(3):159-64. doi: 10.1002/psc.1214.

PMID:
20127854
37.

Nogo receptor 1 regulates formation of lasting memories.

Karlén A, Karlsson TE, Mattsson A, Lundströmer K, Codeluppi S, Pham TM, Bäckman CM, Ogren SO, Aberg E, Hoffman AF, Sherling MA, Lupica CR, Hoffer BJ, Spenger C, Josephson A, Brené S, Olson L.

Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20476-81. doi: 10.1073/pnas.0905390106. Epub 2009 Nov 13.

38.

Structural basis for the inhibition of Mycobacterium tuberculosis glutamine synthetase by novel ATP-competitive inhibitors.

Nilsson MT, Krajewski WW, Yellagunda S, Prabhumurthy S, Chamarahally GN, Siddamadappa C, Srinivasa BR, Yahiaoui S, Larhed M, Karlén A, Jones TA, Mowbray SL.

J Mol Biol. 2009 Oct 23;393(2):504-13. doi: 10.1016/j.jmb.2009.08.028. Epub 2009 Aug 18.

PMID:
19695264
39.

Functionalized 3-amino-imidazo[1,2-a]pyridines: a novel class of drug-like Mycobacterium tuberculosis glutamine synthetase inhibitors.

Odell LR, Nilsson MT, Gising J, Lagerlund O, Muthas D, Nordqvist A, Karlén A, Larhed M.

Bioorg Med Chem Lett. 2009 Aug 15;19(16):4790-3. doi: 10.1016/j.bmcl.2009.06.045. Epub 2009 Jun 14.

PMID:
19560924
40.

Ligands to the (IRAP)/AT4 receptor encompassing a 4-hydroxydiphenylmethane scaffold replacing Tyr2.

Andersson H, Demaegdt H, Vauquelin G, Lindeberg G, Karlén A, Hallberg M.

Bioorg Med Chem. 2008 Jul 15;16(14):6924-35. doi: 10.1016/j.bmc.2008.05.046. Epub 2008 May 27.

PMID:
18556208
41.

Microwave-enhanced alpha-arylation of a protected glycine in water: evaluation of 3-phenylglycine derivatives as inhibitors of the tuberculosis enzyme, glutamine synthetase.

Lagerlund O, Odell LR, Mowbray SL, Nilsson MT, Krajewski WW, Nordqvist A, Karlén A, Larhed M.

Comb Chem High Throughput Screen. 2007 Nov;10(9):783-9.

PMID:
18478959
42.

Evaluation of the amino acid binding site of Mycobacterium tuberculosis glutamine synthetase for drug discovery.

Nordqvist A, Nilsson MT, Röttger S, Odell LR, Krajewski WW, Evalena Andersson C, Larhed M, Mowbray SL, Karlén A.

Bioorg Med Chem. 2008 May 15;16(10):5501-13. doi: 10.1016/j.bmc.2008.04.015. Epub 2008 Apr 11.

PMID:
18462943
43.

Beta-amino acid substitutions and structure-based CoMFA modeling of hepatitis C virus NS3 protease inhibitors.

Nurbo J, Peterson SD, Dahl G, Helena Danielson U, Karlén A, Sandström A.

Bioorg Med Chem. 2008 May 15;16(10):5590-605. doi: 10.1016/j.bmc.2008.04.005. Epub 2008 Apr 6.

PMID:
18434166
44.

Identification of Plasmodium falciparum spermidine synthase active site binders through structure-based virtual screening.

Jacobsson M, Gäredal M, Schultz J, Karlén A.

J Med Chem. 2008 May 8;51(9):2777-86. doi: 10.1021/jm7016144. Epub 2008 Apr 12.

PMID:
18410081
45.

Is it possible to increase hit rates in structure-based virtual screening by pharmacophore filtering? An investigation of the advantages and pitfalls of post-filtering.

Muthas D, Sabnis YA, Lundborg M, Karlén A.

J Mol Graph Model. 2008 Jun;26(8):1237-51. doi: 10.1016/j.jmgm.2007.11.005. Epub 2007 Nov 29.

PMID:
18203638
46.

Hepatitis C virus NS3 protease inhibitors comprising a novel aromatic P1 moiety.

Rönn R, Lampa A, Peterson SD, Gossas T, Akerblom E, Danielson UH, Karlén A, Sandström A.

Bioorg Med Chem. 2008 Mar 15;16(6):2955-67. doi: 10.1016/j.bmc.2007.12.041. Epub 2007 Dec 27.

PMID:
18194867
47.

Modeling binding modes of angiotensin II and pseudopeptide analogues to the AT2 receptor.

Sköld C, Nikiforovich G, Karlén A.

J Mol Graph Model. 2008 Feb;26(6):991-1003. Epub 2007 Aug 26.

PMID:
17936050
48.

Quantitative structure-activity relationships of pine weevil antifeedants, a multivariate approach.

Sunnerheim K, Nordqvist A, Nordlander G, Borg-Karlson AK, Unelius CR, Bohman B, Nordenhem H, Hellqvist C, Karlén A.

J Agric Food Chem. 2007 Nov 14;55(23):9365-72. Epub 2007 Oct 10.

PMID:
17927202
49.

Design, synthesis and evaluation of peptide inhibitors of Mycobacterium tuberculosis ribonucleotide reductase.

Nurbo J, Roos AK, Muthas D, Wahlström E, Ericsson DJ, Lundstedt T, Unge T, Karlén A.

J Pept Sci. 2007 Dec;13(12):822-32.

PMID:
17918768
50.

Virtual screening and bioassay study of novel inhibitors for dengue virus mRNA cap (nucleoside-2'O)-methyltransferase.

Luzhkov VB, Selisko B, Nordqvist A, Peyrane F, Decroly E, Alvarez K, Karlen A, Canard B, Qvist J.

Bioorg Med Chem. 2007 Dec 15;15(24):7795-802. Epub 2007 Aug 29. Erratum in: Bioorg Med Chem. 2008 Mar 15;16(6):3462.

PMID:
17888664

Supplemental Content

Loading ...
Support Center